Skip to main content

Table 1 WST-1 proliferation assay for BT474 cells treated with atRA and trastuzumab

From: Anti-tumor effects of retinoids combined with trastuzumab or tamoxifen in breast cancer cells: induction of apoptosis by retinoid/trastuzumab combinations

  Fraction affected  
Dose atRA Trastuzumab atRA + Tzmab Combination index
0.2 0.17 ± 0.052 0.26 ± 0.009 0.56 ± 0.021 0.19 ± 0.057
0.4 0.28 ± 0.056 0.51 ± 0.006 0.79 ± 0.037 0.01 ± 0.003
0.6 0.33 ± 0.058 0.58 ± 0.012 0.83 ± 0.049 0.01 ± 0.007
1 0.46 ± 0.046 0.62 ± 0.026 0.86 ± 0.042 0.01 ± 0.005
5 0.52 ± 0.061 0.64 ± 0.023 0.85 ± 0.052 0.07 ± 0.046
10 0.55 ± 0.058 0.66 ± 0.030 0.87 ± 0.048 0.10 ± 0.067
  1. Doses of all-trans retinoic acid (atRA) and trastuzumab (Tzmab) in μM and μg/ml, respectively. Each value is the mean of three independent experiments (with eight replicate wells for each treatment) ± standard error.